Capitalizing leadership acumen
for life science innovations

WESTON, Fla.May 21, 2019 /PRNewswire/ -- ZyVersa Therapeutics, Inc., a clinical stage specialty biopharmaceutical company developing first-in-class drugs for inflammatory and renal diseases, is pleased to announce formation of its inaugural Immunology Scientific Advisory Board comprised of some of the world's leading experts in inflammasome research. The Immunology SAB will serve as strategic and scientific advisors to ZyVersa as it advances development of IC 100, our proprietary inflammasome inhibitor uniquely targeting ASC, and as we expand our inflammasome technology platform. The inaugural members of ZyVersa's Immunology Scientific Advisory Board are listed below.